Dynamic Technology Lab Private Ltd Buys Shares of 5,150 Charles River Laboratories International, Inc. (NYSE:CRL)

Dynamic Technology Lab Private Ltd purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,150 shares of the medical research company’s stock, valued at approximately $951,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Versant Capital Management Inc lifted its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. boosted its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Pilgrim Partners Asia Pte Ltd acquired a new position in Charles River Laboratories International during the 4th quarter worth $48,000. Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after purchasing an additional 115 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at about $59,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Down 2.9 %

NYSE:CRL opened at $136.95 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 52-week low of $132.99 and a 52-week high of $258.56. The stock’s 50 day moving average price is $162.49 and its 200 day moving average price is $180.59. The company has a market capitalization of $7.00 billion, a PE ratio of 912.99, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the firm posted $2.46 earnings per share. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on CRL. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a research report on Monday, March 3rd. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Robert W. Baird dropped their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Finally, Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $189.77.

Insider Activity

In related news, CEO James C. Foster purchased 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).